Publications by authors named "Peter Guzzo"

Claim this Profile
A
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.
Jesse Dallery, Jennifer L Miller, Jeff Boissoneault, Lauren Harvey, Lindsey Ives, Peter R Guzzo

J Eat Disord· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous psilocybin induces dose-dependent changes in functional network organization in rat cortex.
Brian H Silverstein, Nicholas Kolbman, Amanda Nelson, Tiecheng Liu, Peter Guzzo

Transl Psychiatry· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for partial agonism in 5-HT receptors.
Kevin Felt, Madeleine Stauffer, Leslie Salas-Estrada, Peter R Guzzo, Dejian Xie

Nat Struct Mol Biol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Structural basis for partial agonism in 5-HT receptors.
Kevin Felt, Madeleine Stauffer, Leslie Salas-Estrada, Peter R Guzzo, Dejian Xie

Nat Struct Mol Biol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psilocybin induces dose-dependent changes in functional network organization in rat cortex.
Brian H Silverstein, Nicholas Kolbman, Amanda Nelson, Tiecheng Liu, Peter Guzzo

bioRxiv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain.
Nicholas Kolbman, Tiecheng Liu, Peter Guzzo, Jim Gilligan, George A Mashour

Curr Biol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSTI-300 (SMP-100); a Novel 5-HT Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome.
Alexander Roberts, Gillian Grafton, Andrew D Powell, Kristian Brock, Chunlin Chen, Peter R Guzzo

J Pharmacol Exp Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bifidenone: Structure-Activity Relationship and Advanced Preclinical Candidate.
Zhongping Huang, Russell B Williams, Steven M Martin, Julie A Lawrence, Vanessa L Norman, Peter R Guzzo

J Med Chem· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders.
Christopher L Cioffi, Peter R Guzzo

Curr Top Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1.
Christopher L Cioffi, Shuang Liu, Mark A Wolf, Peter R Guzzo, Kashinath Sadalapure

J Med Chem· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poster 83 Management of Necrotic Digits on the Inpatient Rehabilitation Unit.
Jerry Thomas, Jesuel Padro-Guzman, Peter T Guzzo

PM R· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.
Cheng Guo, Min Hu, Russell J DeOrazio, Alexander Usyatinsky, Kevin Fitzpatrick, Peter R Guzzo

Bioorg Med Chem· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.
Shuang Liu, Congxiang Zha, Kassoum Nacro, Min Hu, Wenge Cui, Peter R Guzzo

ACS Med Chem Lett· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of diazepinone-based 5-HT3 receptor partial agonists.
David D Manning, Cheng Guo, Zhenjun Zhang, Kristen N Ryan, Jennifer Naginskaya, Peter R Guzzo

Bioorg Med Chem Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From preclinical to clinical development: the example of a novel treatment for obesity.
Nicholas A Moore, Bruce J Sargent, Peter R Guzzo, Matthew D Surman

Neurobiol Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.
Christopher L Cioffi, Mark A Wolf, Peter R Guzzo, Kashinath Sadalapure, Visweswaran Parthasarathy

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D.
Nicholas A Moore, Bruce J Sargent, David D Manning, Peter R Guzzo

ACS Chem Neurosci· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epiminocyclohepta[b]indole analogs as 5-HT6 antagonists.
Alan J Henderson, Peter R Guzzo, Animesh Ghosh, Jagjit Kaur, Jia-Man Koo

Bioorg Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
David D Manning, Christopher L Cioffi, Alexander Usyatinsky, Kevin Fitzpatrick, Liaqat Masih, Peter R Guzzo

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.
Iyassu K Sebhat, Christopher Franklin, Michael M-C Lo, David Chen, James P Jewell, Peter R Guzzo

ACS Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.
Mark Hadden, Dustin M Deering, Alan J Henderson, Matthew D Surman, Michele Luche, Peter R Guzzo

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetrahydrocarboline analogs as MCH-1 antagonists.
Alan J Henderson, Dustin Deering, James F Grabowski, Mark Hadden, Xiaowu Jiang, Peter R Guzzo

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
Matthew D Surman, Emily E Freeman, James F Grabowski, Mark Hadden, Alan J Henderson, Peter R Guzzo

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.
Cheng Guo, Peter R Guzzo, Mark Hadden, Bruce J Sargent, Larry Yet

Bioorg Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Functionalized indazoles as glucocorticoid receptor agonists.
Mei Bai, Grant Carr, Russell J Deorazio, Thomas D Friedrich, Svetlana Dobritsa, Peter R Guzzo

Bioorg Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis